Depreotide

Star0

DB11628ApprovedWithdrawnSmall molecule

Depreotide is an ingredient in the EMA-withdrawn product NeoSpect.

Mechanism: Pharmacologically active on Somatostatin receptor type 5, Somatostatin receptor type 2, and Somatostatin receptor type 3
Curator reviewed
Formula / weight: C₆₅H₉₆N₁₆O₁₂S₂ · 1357.7 g/mol (avg)
Code names: P-829

Resolves to

Compound

UNIINDP0H8E844CAS161982-62-3ChEMBLCHEMBL1908335ChEBI135908

Structure

InChIKeyXXXSJQLZVNKRKX-YQRDHHIGSA-NSMILES

CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=CC=C2)N(C)C(=O)[C@H](CCSCC(=O)NC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(N)=O)NC1=O

Targets

P35346SSTR5P30874SSTR2P32745SSTR3

What you can answer from here — as of August 30, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Depreotide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account